Giulia Casorati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4838445/publications.pdf

Version: 2024-02-01

114 papers	7,950 citations	50170 46 h-index	48187 88 g-index
116 all docs	116 docs citations	116 times ranked	7110 citing authors

#	Article	IF	Citations
1	Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA- Immunodeficient Patients. Science, 1995, 270, 470-475.	6.0	775
2	CD1d-mediated Recognition of an Î±-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution. Journal of Experimental Medicine, 1998, 188, 1521-1528.	4.2	597
3	Expression of two T cell receptor alpha chains: dual receptor T cells. Science, 1993, 262, 422-424.	6.0	486
4	An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells.. Journal of Experimental Medicine, 1994, 180, 1171-1176.	4.2	427
5	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine, 2012, 18, 807-815.	15.2	398
6	CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes. Journal of Experimental Medicine, 2003, 197, 1051-1057.	4.2	217
7	Selection by two powerful antigens may account for the presence of the major population of human peripheral gamma/delta T cells.. Journal of Experimental Medicine, 1991, 173, 1311-1322.	4.2	214
8	Invariant NKT cells sustain specific B cell responses and memory. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3984-3989.	3.3	213
9	Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nature Medicine, 2002, 8, 423-425.	15.2	205
10	Molecular analysis of human gamma/delta+ clones from thymus and peripheral blood.. Journal of Experimental Medicine, 1989, 170, 1521-1535.	4.2	178
11	Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. International Immunology, 1998, 10, 1281-1288.	1.8	159
12	Production of Profibrotic Cytokines by Invariant NKT Cells Characterizes Cirrhosis Progression in Chronic Viral Hepatitis. Journal of Immunology, 2004, 173, 1417-1425.	0.4	141
13	In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4-8- subset.. Journal of Experimental Medicine, 1993, 177, 1763-1771.	4.2	140
14	Activation of invariant NKT cells by Î±GalCer administration protects mice from MOG35â€“55-induced EAE: critical roles for administration route and IFN-Î³. European Journal of Immunology, 2003, 33, 1830-1838.	1.6	132
15	Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma. Journal of Immunology, 2000, 165, 2651-2656.	0.4	127
16	Highâ€frequency and adaptiveâ€like dynamics of human CD1 selfâ€reactive T cells. European Journal of Immunology, 2011, 41, 602-610.	1.6	116
17	T-cell clonality in immune responses. Trends in Immunology, 1999, 20, 262-266.	7.5	115
18	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. European Journal of Immunology, 1995, 25, 1154-1162.	1.6	111

#	Article	IF	Citations
19	T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. European Journal of Immunology, 2002, 32, 2046.	1.6	109
20	Neonatal invariant VÎ±24+ NKT lymphocytes are activated memory cells. European Journal of Immunology, 2000, 30, 1544-1550.	1.6	108
21	Antigen recognition by human T cell receptor gamma-positive lymphocytes. Specific lysis of allogeneic cells after activation in mixed lymphocyte culture.. Journal of Experimental Medicine, 1988, 167, 1517-1522.	4.2	91
22	Up-Regulation of CD1d Expression Restores the Immunoregulatory Function of NKT Cells and Prevents Autoimmune Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2004, 172, 5908-5916.	0.4	90
23	Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help. Journal of Immunology, 2012, 188, 3217-3222.	0.4	90
24	Development of lymphocytes in interleukin 7-transgenic mice. European Journal of Immunology, 1991, 21, 453-460.	1.6	89
25	Selective activation, expansion, and monitoring of human iNKTâ€„cells with a monoclonal antibody specific for the TCR Î±â€chain CDR3 loop. European Journal of Immunology, 2008, 38, 1756-1766.	1.6	89
26	NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood, 2009, 113, 370-376.	0.6	87
27	Rearrangements of immunoglobulin and T cell receptor beta and gamma genes are associated with terminal deoxynucleotidyl transferase expression in acute myeloid leukemia.. Journal of Experimental Medicine, 1987, 165, 879-890.	4.2	86
28	Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4â^' Subset Dynamics and Correlates with Remission State. Journal of Immunology, 2011, 186, 4490-4499.	0.4	85
29	Targeted inactivation of the COP9 signalosome impairs multiple stagesof T cell development. Journal of Experimental Medicine, 2008, 205, 465-477.	4.2	83
30	Dicer-Dependent MicroRNA Pathway Controls Invariant NKT Cell Development. Journal of Immunology, 2009, 183, 2506-2512.	0.4	82
31	CD3+4â^'8â^'WT31â^' (T cell receptor Î³+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. European Journal of Immunology, 1987, 17, 1815-1819.	1.6	81
32	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. Journal of Experimental Medicine, 2014, 211, 1363-1377.	4.2	80
33	Lipid-protein interactions: Biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1022-1026.	3.3	73
34	Cutting Edge: Influence of the TCR VÎ² Domain on the Selection of Semi-Invariant NKT Cells by Endogenous Ligands. Journal of Immunology, 2006, 176, 2064-2068.	0.4	70
35	Intracellular Modulation, Extracellular Disposal and Serum Increase of MiR-150 Mark Lymphocyte Activation. PLoS ONE, 2013, 8, e75348.	1.1	66
36	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. Cell Reports, 2018, 22, 3006-3020.	2.9	62

#	Article	IF	Citations
37	iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells. PLoS ONE, 2010, 5, e8646.	1.1	61
38	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood, 2017, 129, 3440-3451.	0.6	56
39	Targeted Expression of Human CD1d in Transgenic Mice Reveals Independent Roles for Thymocytes and Thymic APCs in Positive and Negative Selection of VÎ±14i NKT Cells. Journal of Immunology, 2005, 175, 7303-7310.	0.4	55
40	The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Experimental Medicine, 2009, 206, 735-742.	4.2	53
41	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. European Journal of Immunology, 1996, 26, 1851-1859.	1.6	52
42	An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. Journal of Immunological Methods, 1996, 196, 181-192.	0.6	51
43	Fine tuning by human CD1e of lipid-specific immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14228-14233.	3.3	51
44	Casting a wider net: Immunosurveillance by nonclassical MHC molecules. PLoS Pathogens, 2019, 15, e1007567.	2.1	49
45	Human T cells expressing the gamma/delta T-cell receptor (TcR-1): C gamma 1- and C gamma 2-encoded forms of the receptor correlate with distinctive morphology, cytoskeletal organization, and growth characteristics.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 1619-1623.	3.3	48
46	A comparison of two techniques for the molecular tracking of specific Tâ€cell responses; CD4+human Tâ€cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+population. Immunology, 1998, 94, 529-535.	2.0	48
47	T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut, 2017, 66, 454-463.	6.1	48
48	CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood, 2007, 110, 251-258.	0.6	47
49	In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. European Journal of Immunology, 1994, 24, 2691-2698.	1.6	45
50	Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood, 2006, 108, 3843-3850.	0.6	45
51	CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Research, 2003, 63, 8481-6.	0.4	45
52	miR-17â^¼92 family clusters control iNKT cell ontogenesis via modulation of TGF-Î² signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8286-E8295.	3.3	44
53	T cell receptor heterogeneity in Î³Î´ T cell clones from intestinal biopsies of patients with celiac disease. European Journal of Immunology, 1993, 23, 499-504.	1.6	41
54	Innate immune responses support adaptive immunity: NKT cells induce B cell activation. Vaccine, 2003, 21, S48-S54.	1.7	41

#	Article	IF	Citations
55	Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor Î² chain repertoire and reduces the level of T-cell oligoclonality. Blood, 2000, 95, 1743-1751.	0.6	38
56	Human peripheral blood lymphocytes bearing T cell receptor gamma/delta. Expression of CD8 differentiation antigen correlates with the expression of the 55-kD, C gamma 2-encoded gamma chain.. Journal of Experimental Medicine, 1988, 168, 2349-2354.	4.2	35
57	Invariant TCR Rather Than CD1d Shapes the Preferential Activities of C-Glycoside Analogues Against Human Versus Murine Invariant NKT Cells. Journal of Immunology, 2009, 183, 4415-4421.	0.4	32
58	iNKTâ€cell help to B cells: A cooperative job between innate and adaptive immune responses. European Journal of Immunology, 2014, 44, 2230-2237.	1.6	32
59	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunology, Immunotherapy, 2015, 64, 99-104.	2.0	32
60	Recruitment of circulating allergen-specific T lymphocytes to the lung on allergen challenge in asthma. Journal of Allergy and Clinical Immunology, 1997, 100, 669-678.	1.5	30
61	Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. International Immunology, 1995, 7, 1741-1752.	1.8	29
62	Human Invariant VÎ±24-JÎ±Q TCR Supports the Development of CD1d-Dependent NK1.1+ and NK1.1â^' T Cells in Transgenic Mice. Journal of Immunology, 2003, 170, 2390-2398.	0.4	29
63	Use of MHC class II tetramers to investigate CD4⁺ T cell responses: Problems and solutions. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1010-1018.	1.1	29
64	Innate-Like Effector Differentiation of Human Invariant NKT Cells Driven by IL-7. Journal of Immunology, 2008, 180, 4415-4424.	0.4	27
65	On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clinical Immunology, 2011, 140, 152-159.	1.4	26
66	Heterogeneity of large granular lymphocyte proliferations: morphological, immunological and molecular analysis in seven patients. British Journal of Haematology, 1987, 66, 187-191.	1.2	25
67	Dual Receptor T-Cells.. Annals of the New York Academy of Sciences, 1995, 756, 66-70.	1.8	25
68	Vaccination with Mouse Mammary Adenocarcinoma Cells Coexpressing B7-1 (CD80) and B7-2 (CD86) Discloses the Dominant Effect of B7-1 in the Induction of Antitumor Immunity. Journal of Immunology, 2000, 164, 698-704.	0.4	23
69	Nonrandom TRGÎ³ variable gene rearrangement in normal human T cells and T cell leukemias. European Journal of Immunology, 1988, 18, 173-178.	1.6	22
70	The T cell receptor Î±Î² V-J shuffling shows lack of autonomy between the combining site and the constant domain of the receptor chains. European Journal of Immunology, 1993, 23, 586-589.	1.6	21
71	Boosting Interleukinâ€12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGRâ€Tagged Nanogold. Small, 2019, 15, e1903462.	5.2	21
72	Molecular and immunological evidence of B-cell commitment in â€œnullâ€•acute lymphoblastic leukaemia. International Journal of Cancer, 1986, 38, 317-323.	2.3	20

#	Article	IF	Citations
73	Restriction of the T-cell receptor V delta gene repertoire is due to preferential rearrangement and is independent of antigen selection. Immunogenetics, 1995, 42, 323-332.	1.2	19
74	Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation. OncoImmunology, 2012, 1, 355-357.	2.1	19
75	Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunology, 2005, 6, 24.	0.9	18
76	The Pathophysiological Relevance of the iNKT Cell/Mononuclear Phagocyte Crosstalk in Tissues. Frontiers in Immunology, 2018, 9, 2375.	2.2	17
77	Phage displayâ€derived recombinant antibodies with TCRâ€like specificity against Î±â€galactosylceramide and its analogues in complex with human CD1d molecules. European Journal of Immunology, 2008, 38, 829-840.	1.6	15
78	Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment. Frontiers in Medicine, 2022, 9, .	1.2	15
79	Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation. Experimental Hematology, 2005, 33, 212-218.	0.2	14
80	Group 1 <scp>CD1</scp>â€restricted T cells and the pathophysiological implications of selfâ€lipid antigen recognition. Tissue Antigens, 2015, 86, 393-405.	1.0	13
81	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in EÎ¼-TCL1 mice through a CD40L-independent mechanism. Blood Advances, 2021, 5, 2817-2828.	2.5	13
82	CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes. European Journal of Immunology, 2005, 35, 806-815.	1.6	12
83	A Subset of CD8Î±Î²+ Invariant NKT Cells in a Humanized Mouse Model. Journal of Immunology, 2015, 195, 1459-1469.	0.4	11
84	Targeting leukemia by CD1c-restricted T cells specific for a novel lipid antigen. OncoImmunology, 2015, 4, e970463.	2.1	11
85	The circulating microRNome demonstrates distinct lymphocyte subsetâ€dependent signatures. European Journal of Immunology, 2016, 46, 725-731.	1.6	11
86	Clonally expanded CD3+, CD4â^', CD8â^' cells bearing the or the T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. Clinical Immunology and Immunopathology, 1991, 60, 371-383.	2.1	10
87	Functional Education of Invariant NKT Cells by Dendritic Cell Tuning of SHP-1. Journal of Immunology, 2013, 190, 3299-3308.	0.4	10
88	Flow cytometry data mining by cytoChain identifiesÂdeterminants of exhaustion and stemness in TCRâ€engineered T cells. European Journal of Immunology, 2021, 51, 1992-2005.	1.6	10
89	MAGE-A3161â€“175 contains an HLA-DRÎ²4 restricted natural epitope poorly formed through indirect presentation by dendritic cells. Cancer Immunology, Immunotherapy, 2007, 57, 207-215.	2.0	9
90	Exploiting CD1-restricted T cells for clinical benefit. Molecular Immunology, 2021, 132, 126-131.	1.0	9

#	Article	IF	Citations
91	Vascular attack and immunotherapy: a â€˜two hitsâ€™ approach to improve biological treatment of cancer. Gene Therapy, 1999, 6, 153-154.	2.3	6
92	Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology. Clinical Cancer Research, 2006, 12, 4949-4957.	3.2	6
93	The CD4⁺ Tâ€cell epitopeâ€binding register is a critical parameter when generating functional HLAâ€DR tetramers with promiscuous peptides. European Journal of Immunology, 2010, 40, 1603-1616.	1.6	6
94	Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy. Cytokine and Growth Factor Reviews, 2017, 36, 117-123.	3.2	6
95	The TCR VÎ´ repertoire and the restricted TCR V gene expression and pairing. Research in Immunology, 1990, 141, 624-625.	0.9	5
96	B Cell Help by CD1d-Rectricted NKT Cells. Antibodies, 2015, 4, 279-294.	1.2	5
97	Potential advantages of CD1-restricted T cell immunotherapy in cancer. Molecular Immunology, 2018, 103, 200-208.	1.0	5
98	Mir106b-25 and Mir17-92 Are Crucially Involved in the Development of Experimental Neuroinflammation. Frontiers in Neurology, 2020, 11, 912.	1.1	5
99	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. Cancers, 2021, 13, 1577.	1.7	5
100	An Efficient Strategy to Induce and Maintain In Vitro Human T Cells Specific for Autologous Non-Small Cell Lung Carcinoma. PLoS ONE, 2010, 5, e12014.	1.1	3
101	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. Nature Communications, 2021, 12, 4844.	5.8	3
102	Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT. Blood, 2016, 128, 4564-4564.	0.6	3
103	Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. Life Science Alliance, 2022, 5, e202101316.	1.3	2
104	An unexpected requirement for CD4⁺ T cells in antiâ€glycolipid antibody responses. Immunology and Cell Biology, 2011, 89, 499-501.	1.0	1
105	Of selfâ€lipids, CD1â€restricted T cells, and contact sensitization. European Journal of Immunology, 2017, 47, 1119-1122.	1.6	1
106	miRâ€21 sustains CD28 signalling and lowâ€affinity Tâ€cell responses at the expense of selfâ€tolerance. Clinical and Translational Immunology, 2021, 10, e1321.	1.7	1
107	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. Blood, 2011, 118, 667-667.	0.6	1
108	B Cell Helper Assays. Methods in Molecular Biology, 2009, 514, 15-26.	0.4	1

#	Article	IF	Citations
109	Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT. Blood, 2018, 132, 2028-2028.	0.6	1
110	TCR Î±/Î² variability in perypheral blood lymphocytes and intestinal mucosa of coeliac and non-coeliac patients. Human Immunology, 1993, 36, 64.	1.2	0
111	The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Cell Biology, 2009, 185, i1-i1.	2.3	0
112	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia.. Blood, 2010, 116, 3764-3764.	0.6	0
113	Abstract A83: Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in Vk*MYC mice.. , 2013, , .		0
114	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. Blood, 2019, 134, 683-683.	0.6	0